Epilepsy Pipeline Appears Robust With 75+ Key Pharma Companies Actively Working in the Therapeutics Segment
Explore our latest breakthroughs in Epilepsy Research. Learn more about our innovative pipeline today! @ Epilepsy Pipeline Outlook
Key Takeaways from the Epilepsy Pipeline Report
In June 2025, Ono Pharmaceutical Co. Ltd announced a Phase 2, Multicenter Open-Label Extension Study to Evaluate the Long-term Safety of Cenobamate in Japanese Subjects With Partial Onset Seizures.
In June 2025, UCB Biopharma SRL conducted a study is to evaluate the long-term safety and tolerability of brivaracetam. EP0156 is designed to assess the long-term safety and tolerability of BRV in pediatric study participants with epilepsy who participated in the neonatal study N01349 [NCG03325439] and/or have participated in the open-label, long-term, follow-up pediatric study N01266 [NCT01364597].
DelveInsight's Epilepsy pipeline report depicts a robust space with 75+ active players working to develop 90+ pipeline therapies for Epilepsy treatment.
The leading Epilepsy Companies such as UCB, SK Life Science, Stoke Therapeutics, Xenon Pharmaceuticals, Epygenix, Bright Minds Biosciences, Neurona Therapeutics, Cevevel Therapeutics, PTC Therapeutics, Addex Pharmaceuticals, Equilibre Biopharmaceuticals B.V., ES Therapeutics Australia Pty Ltd, Overseas Pharmaceuticals, Anavex Life Sciences, Eliem Therapeutics, Ovid Therapeutics, CAMP4 Therapeutics, LifeSplice, Virpax Pharmaceuticals, Neuroene Therapeutics and others.
Promising Epilepsy Pipeline Therapies such as Stiripentol, Lacosamide, Levetiracetam 250 mg, Cenobamate, Ganaxolone, Pregabalin, and others.
Stay informed about the cutting-edge advancements in Epilepsy treatments. Download for updates and be a part of the revolution in Neurology Care @ Epilepsy Clinical Trials Assessment
Epilepsy Emerging Drugs Profile
EPX-100: Harmony Biosciences
EPX-100 is a potential new treatment being for people with Dravet syndrome and Lennox-Gastaut Syndrome. EPX-100 is a repurposed antihistamine, which was used in the 1950s and 1960s to treat itchiness. The medication is thought to be able to suppress seizures through its action on the serotonin signaling pathways, a mechanism that is different from its anti-histaminic properties. Serotonin is a chemical messenger present in many parts of the brain. Scientists think that people with Dravet syndrome and Lennox-Gastaut Syndrome may have alterations in the serotonin signaling pathway, but the exact problems are not known. Likewise, precisely how EPX-100 affects serotonin systems in the brain to reduce seizures is still unclear. According to company's pipeline the drug is in the Phase III stage of its development for the treatment of Dravet syndrome and is in the Phase II stage of its development for the treatment of Lennox-Gastaut Syndrome.
BMB-101: Bright Minds Biosciences
BMB-101, a 5-HT2C selective and biased agonist, has demonstrated compelling activity in a host of in-vitro and in-vivo non-clinical tests. Compared to Locaserin, BMB-101 exhibits strong Gq signaling coupled with minimal beta-arrestin recruitment. Mechanistically, Serotonin (5- Hydroxytryptamine, 5-HT) is a monoamine neurotransmitter widely expressed in the central nervous system, and drugs modulating 5-HT have made a major impact in mental health disorders. Central 5-HT systems have long been associated with the control of ingestive behavior and the modulation of behavioral effects of psychostimulants, opioids, alcohol and nicotine. Results of clinical trials and animal studies indicate that 5-HT2C up receptor agonists may have therapeutic potential in the treatment of addiction by decreasing the intake of opioids as well as impulsive behavior that can escalate compulsive drug use. Currently the drug is in Phase II stage of Clinical trial evaluation for the treatment of Epilepsy.
STK-001: Stoke Therapeutics
STK-001 is an investigational new medicine for the treatment of Dravet syndrome currently being evaluated in ongoing clinical trials. Stoke believes that STK-001, a proprietary antisense oligonucleotide (ASO), has the potential to be the first disease-modifying therapy to address the genetic cause of Dravet syndrome. STK-001 is designed to upregulate NaV1.1 protein expression by leveraging the non-mutant (wild-type) copy of the SCN1A gene to restore physiological NaV1.1 levels, thereby reducing both occurrence of seizures and significant non-seizure comorbidities. Currently the drug is in Phase III stage of Clinical trial evaluation for the treatment of Dravet Syndrome.
NRTX-1001: Neurona Therapeutics
NRTX-1001 inhibitory neurons are targeted to the seizure-onset zone to enhance GABAergic inhibition, reduce seizure activity, and repair the affected neural network. NRTX-1001 is delivered as a single, one-time dose and is intended to persist and provide long-term seizure suppression. In preclinical studies, NRTX-1001 has provided seizure-freedom to the majority of the cell treatment group and has not shown signs of dose-limiting toxicity. The preclinical safety and efficacy data have led to an FDA-cleared Phase I/II clinical trial of NRTX-1001 for drug-resistant temporal lobe epilepsy.
IAMA-6: IAMA Therapeutics
IAMA-6 is an orally administered small molecule therapeutics designed to directly target and inhibit NKCC1-associated neuronal hyperexcitability. The elevated activity of NKCC1 is implicated in various pathological conditions, underscoring the significant potential of NKCC1 inhibition in the treatment of both idiopathic and secondary forms of autism (autism spectrum disorder, or ASD), refractory epilepsy, Dravet Syndrome, and other neurological disorders. With the capability to be applied across multiple central nervous system (CNS) indications, IAMA-6 has demonstrated its safety and favorable tolerability in pre-clinical studies. Currently the drug is in Phase I stage of Clinical trial evaluation for the treatment of Epilepsy.
The Epilepsy Pipeline Report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Epilepsy with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Epilepsy Treatment.
Epilepsy Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Epilepsy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Epilepsy market.
Learn more about Epilepsy Drugs opportunities in our groundbreaking Epilepsy research and development projects @ Epilepsy Unmet Needs
Epilepsy Companies
UCB, SK Life Science, Stoke Therapeutics, Xenon Pharmaceuticals, Epygenix, Bright Minds Biosciences, Neurona Therapeutics, Cevevel Therapeutics, PTC Therapeutics, Addex Pharmaceuticals, Equilibre Biopharmaceuticals B.V., ES Therapeutics Australia Pty Ltd, Overseas Pharmaceuticals, Anavex Life Sciences, Eliem Therapeutics, Ovid Therapeutics, CAMP4 Therapeutics, LifeSplice, Virpax Pharmaceuticals, Neuroene Therapeutics and others.
Epilepsy Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Oral
Intravenous
Subcutaneous
Parenteral
Topical
Epilepsy Products have been categorized under various Molecule types such as
Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy
Discover the latest advancements in Epilepsy treatment by visiting our website. Stay informed about how we're transforming the future of Neurology @ Epilepsy Market Drivers and Barriers, and Future Perspectives
Scope of the Epilepsy Pipeline Report
Coverage- Global
Epilepsy Companies- UCB, SK Life Science, Stoke Therapeutics, Xenon Pharmaceuticals, Epygenix, Bright Minds Biosciences, Neurona Therapeutics, Cevevel Therapeutics, PTC Therapeutics, Addex Pharmaceuticals, Equilibre Biopharmaceuticals B.V., ES Therapeutics Australia Pty Ltd, Overseas Pharmaceuticals, Anavex Life Sciences, Eliem Therapeutics, Ovid Therapeutics, CAMP4 Therapeutics, LifeSplice, Virpax Pharmaceuticals, Neuroene Therapeutics and others.
Epilepsy Pipeline Therapies- Stiripentol, Lacosamide, Levetiracetam 250 mg, Cenobamate, Ganaxolone, Pregabalin, and others.
Epilepsy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Epilepsy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Epilepsy Pipeline on our website @ Epilepsy Emerging Drugs and Companies
Table of Contents
Introduction
Executive Summary
Epilepsy: Overview
Pipeline Therapeutics
Therapeutic Assessment
Epilepsy– DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
EPX-100: Harmony Biosciences
Mid Stage Products (Phase II)
BMB-101: Bright Minds Biosciences
Early Stage Products (Phase I)
IAMA-6: IAMA Therapeutics
Preclinical and Discovery Stage Products
NT102: Neuroene Therapeutics
Inactive Products
Epilepsy Key Companies
Epilepsy Key Products
Epilepsy- Unmet Needs
Epilepsy- Market Drivers and Barriers
Epilepsy- Future Perspectives and Conclusion
Epilepsy Analyst Views
Epilepsy Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/epilepsy-pipeline-insight
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
26 minutes ago
- CTV News
Trial opens against Meta CEO Mark Zuckerberg and other leaders over Facebook privacy violations
Meta Founder and CEO Mark Zuckerberg speaks at LlamaCon 2025, an AI developer conference, in Menlo Park, Calif., on April 29, 2025. (Jeff Chiu / AP Photo) WILMINGTON, Del. -- An US$8 billion class action investors' lawsuit against Meta CEO Mark Zuckerberg and company leaders -- current and former -- began Wednesday, with claims stemming from the 2018 privacy scandal involving the Cambridge Analytica political consulting firm. Investors allege in their lawsuit that Meta did not fully disclose the risks that Facebook users' personal information would be misused by Cambridge Analytica, a firm that supported Donald Trump's successful Republican presidential campaign in 2016. Shareholders say Facebook officials repeatedly and continually violated a 2012 consent order with the Federal Trade Commission under which Facebook agreed to stop collecting and sharing personal data on platform users and friends without their consent. Facebook later sold user data to commercial partners in direct violation of the consent order and removed disclosures from privacy settings that were required under consent order, the lawsuit alleges. The fallout led to Facebook agreeing to pay a $5.1 billion penalty to settle FTC charges. The social media giant also faced significant fines in Europe and reached a $725 million privacy settlement with users. Now shareholders want Zuckerberg and others to reimburse Meta for the FTC fine and other legal costs, which the plaintiffs estimate total more than $8 billion. The first trial witness, privacy expert Neil Richards, testified Monday morning for the shareholders. 'Facebook's privacy disclosures were misleading,' said Richards, a professor at Washington University Law School. In later testimony, Jeffrey Zients, who served on Facebook's board from 2018 to 2020, testified that consumer privacy and user data were priorities for both management and the board. Nonetheless, he supported settling with the FTC as it investigated potential violations of the 2012 consent order, so the company could move forward. 'It was difficult because this was a lot of money, but I think it was better than the alternative,' Zients said. Asked if the board considered making its founder a party to the settlement, he said Zuckerberg was 'essential' to running the company. And, Zients, who served in both the Obama and Biden administrations, said, 'there was no indication that he had done anything wrong.' The case is expected to run through late next week and include testimony from both Zuckerberg and former chief operating officer Sheryl Sandberg. Other witnesses expected in Delaware Chancery Court, where Facebook parent Meta Platforms Inc. is incorporated, include board member Marc Andreessen and former board member Peter Thiel. The judge is not expected to rule for several months. Meta had hoped the Supreme Court would dismiss the case. Justices heard arguments in November before deciding they should not have taken it up. The high court dismissed the company's appeal, leaving in place an appellate ruling allowing the case to go forward. -- Maryclaire Dale and Barbara Ortutay, The Associated Press Ortutay reported from San Francisco.
Globe and Mail
26 minutes ago
- Globe and Mail
Obesity Pipeline Appears Robust With 80+ Key Pharma Companies Actively Working in the Therapeutics Segment
DelveInsight's ' Obesity Pipeline Insigh t 2025 ' report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in Othe besity pipeline landscape. It covers the Obesity pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Obesity therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Obesity pipeline products in this space. Stay ahead with the latest insights! Download DelveInsight's comprehensive Obesity Pipeline Report to explore emerging therapies, key Obesity Companies, and future Obesity treatment landscapes @ Obesity Pipeline Outlook Report Key Takeaways from the Obesity Pipeline Report In July 2025, Carmot Therapeutics Inc. announced a study to evaluate the efficacy and safety of CT-388 at low, middle, and high doses in participants who are overweight or obese with Type 2 diabetes mellitus (T2DM). In July 2025, Innovent Biologics (Suzhou) Co. Ltd. conducted a study is a multicenter, randomized, partially double-blind (double-blind in both the IBI362 group and the placebo group, with the tirbopeptide group open), placebo and active drug controlled design study. In July 2025, Zealand Pharma organized a study is to compare dose levels of petrelintide versus placebo with regards to effect on body weight, safety, and tolerability. Obesity is a chronic disease with a rapidly increasing prevalence associated with significant comorbidities. Petrelintide is a long-acting amylin analog in development for weight management. In July 2025, Eli Lilly and Company conducted a study is to determine if combining tirzepatide with mibavademab will result in more weight loss in adult participants than tirzepatide alone. The study will last about 74 weeks and may include up to 19 visits. In July 2025, Rhythm Pharmaceuticals Inc. organized a Phase 3 Multiple Independent Sub-studies of Setmelanotide in Patients With POMC/PCSK1, LEPR, NCOA1(SRC1), or SH2B1 Gene Variants in the Melanocortin-4 Receptor Pathway. DelveInsight's Obesity pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Obesity treatment. The leading Obesity Companies such as Zealand Pharma, Sciwind Biosciences, Genexine, Sirnaomics, Sparrow Pharmaceuticals, Shionogi, Regor Pharmaceuticals, Innovent Biologics, Pfizer, NodThera Limited, Boehringer Ingelheim, Fractyl Health, TransThera, Clearmind Medicine, PegBio, Biolingus, and others. Promising Obesity Therapies such as APHD-012, Bimagrumab, Semaglutide, CT-868, GLY-200, Bremelanotide, and others. Discover how the Obesity treatment paradigm is evolving. Access DelveInsight's in-depth Obesity Pipeline Analysis for a closer look at promising breakthroughs @ Obesity Clinical Trials and Studies Obesity Emerging Drugs Survodutide: Zealand Pharma Survodutide (BI 456906) is a long-acting glucagon/GLP-1 receptor dual agonist for once-weekly subcutaneous administration that activates two key gut hormone receptors simultaneously and may offer better efficacy than current single-hormone receptor agonist treatments. Survodutide is targeting the treatment of obesity and nonalcoholic steatohepatitis (NASH). Boehringer Ingelheim is advancing survodutide into three global Phase III trials in people living with overweight or obesity. Ecnoglutide: Sciwind Biosciences Glucagon-like peptide-1 (GLP-1) analogs are effective therapies in managing type 2 diabetes, obesity, and have demonstrated clinical potential as a treatment for NASH. Ecnoglutide (XW003) is a novel, cAMP signaling biased, long-acting GLP-1 analogue optimized for improved biological activity, cost-effective manufacturing, and once weekly dosing. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Obesity. CT-868: Carmot Therapeutics CT-868 is a dual GLP-1 and GIP receptor modulator with a unique pharmacological profile optimized for improved tolerability at the GLP-1 receptor. The combined action of GLP-1 and GIP results in greater body weight loss and glucose control. CT-868 is dosed once daily to maximize efficacy and tolerability. CT-868 dual agonist candidate was discovered using the chemotype evolution technology as a peptide-small molecule hybrid compound, able to mimic the native GLP-1 hormone. In the Phase I trial, CT-868 demonstrated compelling pharmacodynamic activity across several clinical measures in overweight and obese healthy individuals a safe and generally well-tolerated profile. Carmot Therapeutics is now expanding the observations in overweight and obese patients with type 2 diabetes to demonstrate CT-868's effects on glycemic control, weight loss, and tolerability. Currently, the drug is in the Phase II stage of development to treat obesity. DD01: D&D Pharmatech DD01 is a proprietary, imbalanced dual agonist of GLP-1 and glucagon receptors with a half-life of 11 days in non-human primates. DD01 is being developed as a potential disease-modifying agent for obesity and liver fatty disease. Treatment with DD01 caused weight loss, reduced liver fat, and improved glucose tolerance in preclinical obesity, diabetes, and fatty liver models. In preclinical models of diabetes and nonalcoholic fatty liver disease (NAFLD), DD01 could reduce weight and blood sugar and improve insulin sensitivity and lipid and fat metabolism, which could ameliorate NASH. DD01 demonstrated greater efficacy in preclinical models than semaglutide, an approved GLP-1R receptor agonist; from a mechanical perspective, the effect of DD01 persisted after cessation of treatment. It is currently being evaluated in Phase I clinical trial to investigate the safety, tolerability, PK, and PD of DD01 administered by subcutaneous (SC) injection in overweight/obese subjects with type 2 diabetes mellitus and nonalcoholic fatty liver disease (NAFLD). The Obesity pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Obesity with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Obesity Treatment. Obesity Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Obesity Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Obesity market. Get a detailed analysis of the latest innovations in the Obesity pipeline. Explore DelveInsight's expert-driven report today! @ Obesity Unmet Needs Obesity Companies Zealand Pharma, Sciwind Biosciences, Genexine, Sirnaomics, Sparrow Pharmaceuticals, Shionogi, Regor Pharmaceuticals, Innovent Biologics, Pfizer, NodThera Limited, Boehringer Ingelheim, Fractyl Health, TransThera, Clearmind Medicine, PegBio, Biolingus, and others. Obesity pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Obesity Products have been categorized under various ROAs such as Oral Parenteral Intravenous Subcutaneous Topical Obesity Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Download DelveInsight's latest report to gain strategic insights into upcoming Obesity Therapies and key Obesity Developments @ Obesity Market Drivers and Barriers, and Future Perspectives Scope of the Obesity Pipeline Report Coverage- Global Obesity Companies- Zealand Pharma, Sciwind Biosciences, Genexine, Sirnaomics, Sparrow Pharmaceuticals, Shionogi, Regor Pharmaceuticals, Innovent Biologics, Pfizer, NodThera Limited, Boehringer Ingelheim, Fractyl Health, TransThera, Clearmind Medicine, PegBio, Biolingus, and others. Obesity Therapies- APHD-012, Bimagrumab, Semaglutide, CT-868, GLY-200, Bremelanotide, and others. Obesity Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Obesity Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Which companies are leading the race in Obesity drug development? Find out in DelveInsight's exclusive Obesity Pipeline Report—access it now! @ Obesity Emerging Drugs and Major Companies Table of Contents Introduction Executive Summary Obesity Overview Obesity Pipeline Therapeutics Obesity Therapeutic Assessment Late Stage Products (Phase III) Survodutide: Zealand Pharma Drug profiles in the detailed report….. Mid Stage Products (Phase II) CT-868: Carmot Therapeutics Drug profiles in the detailed report….. Early Stage Products (Phase I) DD01: D&D Pharmatech Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug name: Company name Drug profiles in the detailed report….. Inactive Obesity Products Obesity Key Companies Obesity Key Products Obesity Unmet Needs Obesity Market Drivers Obesity Market Barriers Obesity Future Perspectives and Conclusion Obesity Analyst Views Obesity Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Globe and Mail
an hour ago
- Globe and Mail
Sturm, Ruger & Company, Inc. to Report Second Quarter 2025 Financial Results on Wednesday, July 30
Sturm, Ruger & Company, Inc. (NYSE-RGR) will announce its financial results for the second quarter 2025 and file its Quarterly Report on Form 10-Q on Wednesday, July 30, 2025, after the close of the stock market. On Thursday, July 31, 2025, Sturm, Ruger will host a webcast at 9:00 a.m. ET to discuss the second quarter operating results. Interested parties can listen to the webcast via this link or by visiting Those who wish to ask questions during the webcast will need to pre-register prior to the meeting. About Sturm, Ruger Sturm, Ruger & Co., Inc. is one of the nation's leading manufacturers of rugged, reliable firearms for the commercial sporting market. With products made in America, Ruger offers consumers almost 800 variations of more than 40 product lines, across both the Ruger and Marlin brands. For over 75 years, Ruger has been a model of corporate and community responsibility. Our motto, 'Arms Makers for Responsible Citizens ®,' echoes our commitment to these principles as we work hard to deliver quality and innovative firearms. The Company may, from time to time, make forward-looking statements and projections concerning future expectations. Such statements are based on current expectations and are subject to certain qualifying risks and uncertainties, such as market demand, sales levels of firearms, anticipated castings sales and earnings, the need for external financing for operations or capital expenditures, the results of pending litigation against the Company, the impact of future firearms control and environmental legislation, and accounting estimates, any one or more of which could cause actual results to differ materially from those projected. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date made. The Company undertakes no obligation to publish revised forward-looking statements to reflect events or circumstances after the date such forward-looking statements are made or to reflect the occurrence of subsequent unanticipated events.
